Q-omics provides the consensus-scored PEX14 profile across patient tissues and cancer cell-line models. PEX14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PEX14 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PEX14 RNA expression shows 18,223 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where PEX14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX14 survival associations across molecular data types. PEX14 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX14 RNA expression–survival associations across cancer types. High PEX14 expression shows unfavorable associations in ACC, KICH, LUSC and LGG, but favorable associations in SCLC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PEX14 RNA expression.
This table summarizes PEX14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PEX14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX14 shows lower tumor expression in KICH, BLCA and LUAD and higher tumor expression in HNSC, STAD and COAD. The KICH box plot shows higher PEX14 RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with PEX14 in patient tissues and cancer cell lines. In patient samples, PEX14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
